Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Free Cash Flow (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Free Cash Flow for 2 consecutive years, with -$6.4 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 91.65% to -$6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.4 million through Dec 2025, up 69.68% year-over-year, with the annual reading at $77229.0 for FY2025, 100.53% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$6.4 million at Neuphoria Therapeutics, down from -$3.8 million in the prior quarter.
  • The five-year high for Free Cash Flow was $11.5 million in Q1 2025, with the low at -$6.4 million in Q4 2025.